No Data
Cathie Wood's ARK Investment Buys 223.5K Shares of Intellia Therapeutics Today
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $60 to $90
Positive Buy Rating for Intellia Therapeutics Amid Promising Trial Results for Nex-z in ATTR-CM
Intellia Therapeutics Price Target Lowered to $70 From $80 at Wells Fargo
Intellia Therapeutics' NTLA-2001 Shows Promising Potential With Positive Phase 1 Data and Accelerated Phase 3 Enrollment
Intellia Therapeutics Price Target Cut to $70.00/Share From $80.00 by Wells Fargo
No Data
No Data
三和巴菲特 : Have you cried today? Baby
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 :
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 : Laughed.
71179109 : Intellia - 20% yesterday